Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy

Trial Profile

Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy; Amyloidosis
  • Focus Expanded access; Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top